Skip to content

Post-transplant lymphoproliferative disorders (NORD)



Patient care

Information for patients and families

The Primary School
Glut1 Deficiency Foundation
The National Organization for Rare Disorders (NORD)
Narcolepsy (NORD)
Adrenoleukodystrophy (NORD)
Zellweger spectrum disorders (NORD)
Glycogen storage disease type II (NORD)
Metachromatic leukodystrophy (NORD)
Gaucher disease (NORD)
Niemann-Pick disease types A and B (NORD)
Fabry disease (NORD)
Tay-Sachs disease (NORD)
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Phenylketonuria (NORD)
Cystinuria (NORD)
Aromatic L-amino acid decarboxylase deficiency (NORD)
Cerebrotendinous xanthomatosis (NORD)
Classical homocystinuria (NORD)
Autoimmune polyglandular syndrome type 1 (NORD)
Thyroid eye disease (NORD)
Opsoclonus myoclonus syndrome (NORD)
Thyroid eye disease (NORD)
Recurrent pericarditis (NORD)
Eosinophilic esophagitis (NORD)
Short bowel syndrome (NORD)
Bile synthesis disorders (NORD)
Cyclic vomiting syndrome (NORD)
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Myelofibrosis (NORD)
Warm autoimmune hemolytic anemia and cold agglutinin (NORD)
Sickle cell disease (NORD)
Thrombotic thrombocytopenic purpura
Waldenstrom macroglobulinemia (NORD)
Post-transplant lymphoproliferative disorders (NORD)
Cytomegalovirus infection after transplant (NORD)
Congenital athymia (NORD)
Severe chronic neutropenia (NORD)
Mycobacterium avium complex (NORD)
Congenital cytomegalovirus (NORD)
Opsoclonus myoclonus syndrome (NORD)
Spinocerebellar ataxia (NORD)
Early infantile epileptic encephalopathy (NORD)
IgA nephropathy (NORD)
Focal segmental glomerulosclerosis (NORD)
Alagille syndrome (NORD)
NGLY1 deficiency (NORD)
PIK3CA-related overgrowth spectrum (NORD)
Gorlin Syndrome Alliance

Content Reviewers:

Posttransplant lymphoproliferative disorders, or PTLDs, are uncontrolled growths of cells called lymphocytes that may occur in transplant recipients after receiving a solid organ, such as a kidney or a lung, or stem cells.

Transplant recipients require medications to suppress their immune systems which may contribute to the development of a PTLD.

Normally, immune cells can differentiate between healthy “self” and “other” cells by inspecting for the presence or absence of the normal “self” major histocompatibility complexes, also called human leukocyte antigens, present on the surface of every cell that contains a nucleus.

Healthy “self” cells are left alone.

“Others” include cells from other people or donors and “self” cells that are infected, damaged, or stressed.

Lymphocytes, are a class of rapidly dividing cells and, therefore, tends to develop mutations more often.

B-lymphocytes, or B-cells, work to develop antibodies toward invading microbes.

There’s also two types of T-lymphocytes, or T-cells.

Cytotoxic T-cells can directly destroy “other” cells and helper T-cells assist other immune cells.

Normally, if B-cells start to replicate out of control, it's the T-cells that keep them in check, and keep the immune response organized.

When people receive a transplanted organ or stem cells, they also must take immunosuppressive medications to prevent the immune system from rejecting, or attacking, the transplant.

In PTLDs, immunosuppression also prevents the destruction of abnormal lymphocytes that exhibit uncontrolled replication.

Resulting uncontrolled growth of lymphocytes can either be a benign hyperplasia, meaning there’s a large collection of noncancerous cells, or the cells can become malignant, resulting in a cancer called lymphoma.

While PTLD may result from the overproduction of T-cells, it is more typically associated with the overproduction of B-cells.


Post-transplant lymphoproliferative disorders (PTLDs) are a group of lymphoid neoplasms characterized by uncontrolled growths of lymphocytes. It occurs after someone has received a solid organ or stem cell transplant that requires immunosuppressive medications to prevent transplant rejection. PTLDs are caused by Epstein-Barr virus (EBV) infection and can originate in either type of lymphocyte: B-cells or T-cells. Diagnosis involves blood tests, a biopsy, and imaging, while treatment may include surgery, chemotherapy, and radiation.